Switch Datacenters’ Amsterdam 1 Datacenter Achieves OCP-Ready™ Status
SAN JOSE, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- The Open Compute Project (OCP) Foundation has granted Switch Datacenters from Amsterdam, the Netherlands the prestigious OCP Ready™ status, which means that the Switch AMS1 site complies with all site requirements for a colocation service provider to be able serve OCP customers and their hardware in its facilities.
Switch Datacenters is already a long time contributor to the global OCP community and in its role as challenger in the rapidly growing Amsterdam data center market, well known for its innovative designs and technology choices,
Amsterdam, the Netherlands, March 13th , 2019: After several years of working with the Open Compute Project (OCP) Foundation and actively contributing to the OCP colocation standards, the company has successfully audited against OCP’s checklist for compliance and becomes one of the first European data centers (DC) to achieve OCP-Ready™ status. Accordingly, the Amsterdam AMS1 data center becomes a listed Colo Solution Provider on the OCP Marketplace.
Switch Datacenters runs three high-end sites in the Amsterdam region and offers colocation services in the fastest growing European metropolitan data center market, Amsterdam. Using a unique, patented own design, Switch Datacenters is amongst the greenest DC’s in Europe with a PuE of <1,15.
The three data centers operated by Switch have a total white space floor area of around 8000 m² / 86,000 ft².
Next to running their own colocation retail brand, Switch Datacenters also offers their unique design, build and operational skills as a wholesale service to international customers, facilitating the growing demand of companies who want to have their own highly connected, private data center in Amsterdam, securely managed by Switch on basis of a Service Level Agreement.
The Switch Datacenters AMS1 datacenter is located at a highly connected location in the Amsterdam South-East business district which is known for having one of the highest densities of international backbone carriers in the world.
The AMS1 data center will expand in the adjacent building with an additional whitespace of 1,560 m² and 5.4 MW ICT power. By achieving the OCP Ready™ status, Switch is now also able to offer this unique site development and colocation site to customers requiring a high-end, well-connected OCP Ready™site at a scarce AAA location in Amsterdam.
In October 2018, Switch Datacenters, Rittal and Circle B jointly announced the opening of the first European Experience Center for OCP technology, also located in the AMS1 site of Switch Datacenters. The Experience Center is meant to help the OCP Community to increase the understanding and awareness of the advantages of OCP Hardware and OCP design architectures, and provides a real-life demo environment for customers to get introduced to OCP.
“While the data center market is exploding on a worldwide scale, we need to continuously keep looking for more efficient, smarter and greener solutions to be able to compete. OCP is one of the game-changing trends, and innovation is for us the only answer to grow. That is why Switch Datacenters is eager to cooperate and share our knowledge and learnings in an open community like the globlal OCP Community, and we welcome believers in OCP technology to our Amsterdam facility‘’ says Edgar van Essen, Managing Director of Switch Datacenters.
Steve Helvie, VP of Channel Development at OCP said, “The EMEA region has been identified as a primary region for OCP technology growth, which overall has a forecast 59% CAGR for the next five years. Colocation facility providers are a key to facilitating the use of OCP Hardware, so OCP is delighted to announce that Switch Datacenters – one of the most innovative data center developments in Europe –is an official provider of qualified data center white space for OCP deployments.”
Press Contact Switch Datacenters
Tel.: +31 20 691 6424 firstname.lastname@example.org
Photos accompanying this announcement are available:
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Blackhawks, Flyers, Sabres and Lightning Headline the 2019 NHL Global Series21.3.2019 15:34:00 CET | Pressemelding
Chicago Blackhawks and Philadelphia Flyers to Open Regular Season in Prague, Czech Republic on Oct. 4 Buffalo Sabres and Tampa Bay Lightning to Face Off in a Pair of Games in Stockholm, Sweden on Nov. 8 and Nov. 9 2019 NHL Global Series Challenge to feature Blackhawks vs. Eisbären Berlin on Sept. 29 in Berlin, Germany and Flyers vs. Lausanne HC on Sept. 30 in Lausanne, Switzerland Tickets to Games in Berlin, Prague and Stockholm Available for Purchase on Wednesday, March 27; Tickets to Game in Lausanne Available for Purchase on Wednesday, April 10 NEW YORK/TORONTO, March 21, 2019 (GLOBE NEWSWIRE) -- The National Hockey League (NHL) and the National Hockey League Players’ Association (NHLPA), in conjunction with Live Nation Sweden, today announced that the Buffalo Sabres, Chicago Blackhawks, Philadelphia Flyers and Tampa Bay Lightning will participate in the 2019 NHL Global Series. The Chicago Blackhawks and Philadelphia Flyers will play their 2019-20 season-opening game against each ot
Farmako: World's Largest Import Contract for Pharmaceutical Cannabis21.3.2019 15:10:00 CET | Pressemelding
German Farmako secures 50 tonnes of flowers and oils from Polish company Pharmacann Polska FRANKFURT, March 21, 2019 (GLOBE NEWSWIRE) -- Farmako will import 50 tonnes of pharmaceutical cannabis from Pharmacann Polska into the European market over the next four years. This provides the basis for a reliable supply of pharmaceutical cannabis for millions of patients in the European healthcare system. The company expects a total revenue of several hundred million Euros from the agreed exclusive partnership. Founded in September 2018, Farmako now has grown to 40 employees and is distributing high-quality pharmaceutical cannabis to German pharmacies since March 2019. This is the biggest Cannabis contract to date, and the first big contract without participation of a Canadian LP. Farmako has signed an exclusive and binding agreement to import and distribute 50 tons of pharmaceutical cannabis over four years. Farmako and Pharmacann Polska enter strategic partnership to develop custom tailored
NexOptic Appoints Rich Geruson, Former Lexmark CEO, to Board of Directors21.3.2019 14:00:00 CET | Pressemelding
VANCOUVER, British Columbia, March 21, 2019 (GLOBE NEWSWIRE) -- NexOptic Technology Corp. ("NexOptic" or the "Company") (TSX VENTURE: NXO) (OTCQX: NXOPF) (FRANKFURT: E3O1) is pleased to announce that Richard J. (Rich) Geruson has joined its Board of Directors, effective immediately. Mr. Geruson’s experience spans CEO roles at Lexmark International, Phoenix Technologies and VoiceSignal Technologies, and Senior Vice President and executive positions at Nokia, IBM, Toshiba, and McKinsey & Co. As CEO of Lexmark International, a multibillion-dollar imaging technology and solutions company with 10,000 employees, he grew printer sales faster than at any time in the preceding 10 years while simultaneously executing extensive process reengineering, transforming the business from negative EBITDA and high debt to positive multi-hundred-million-dollar EBITDA and a healthy debt profile. While CEO of Phoenix Technologies, he achieved consistently high profit year-over-year for six years straight in
Standard Lithium Announces Closing of $11.4 Million Bought Deal Including Partial Exercise of Over-Allotment Option21.3.2019 14:00:00 CET | Pressemelding
VANCOUVER, British Columbia, March 21, 2019 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTCQX: STLHF) (FRA: S5L) is pleased to announce that it has closed its previously announced bought deal offering (the “Offering”), including the partial exercise of the over-allotment option. A total of 11,390,500 units (the “Units”) of the Company were issued at a price of $1.00 per Unit for gross proceeds of $11,390,500. Each Unit is comprised of one common share and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company at an exercise price of $1.30 per share, subject to adjustment in certain events, until March 21, 2022. The Units were offered and sold by way of a short form prospectus filed in each of the provinces of Canada, excluding Quebec, and offered and sold elsewhere outside of Canada on a private placement
Crown Bioscience to Present Latest Advancements in Preclinical and Translational Platforms at AACR Annual Meeting 201921.3.2019 13:30:00 CET | Pressemelding
15 posters present data from novel models to evaluate new cancer therapeutics SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the presentation of 15 scientific posters at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, GA from March 29 to April 3. The scientific posters highlight the latest advancements in CrownBio’s integrated oncology and immuno-oncology platforms built on the world’s largest and unique experimental model libraries, including patient-derived xenografts (PDXs), innovative humanized mouse models, GEMM, syngeneic mouse tumor homografts, PDX derived organoids (PDXO), and uniquely developed analytic methods. Featured posters will present data from novel models that enable detailed evaluation of new cancer therapeutics, including targeted cancer i
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease21.3.2019 12:00:00 CET | Pressemelding
Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia. The decision to stop the trials is based on results of a futility analysis conducted by an independent data monitoring committee, which indicated the trials were unlikely to meet their primary endpoint upon completion. The recommendation to stop the studies was not based on safety concerns. “This disappointing news confirms the complexity of treating Alzheimer’s disease and the need to further advance knowledge in neuroscience. We are incredibly grateful to all the Alzheimer’s disease pa